
MSMilan 2023
Featured articles


Real-world data supports ocrelizumab prior to conception

CONTENTS
Online First
Progressive MS
Early initiation of highly active treatment associated with a lower risk of SPMS
Ocrelizumab more effective than interferon/glatiramer acetate in older MS patients
Paediatric MS

Prioritising high efficacy therapies in children with MS
Omega-3 polyunsaturated fatty acids associated with lower risk of MS activity
NMOSD & MOGAD

An update on evolving treatment algorithms for NMOSD and MOGAD
Switching from rituximab to C5 complement inhibitors is safe in AQP4+ NMOSD
Women’s Health
Rate of grey matter brain atrophy accelerates after menopause

Real-world data supports ocrelizumab prior to conception
Miscellaneous
New insights into the contribution of EBV to MS pathogenesis

COVID-19 infection associated with higher MS relapse rate
Telerehabilitation effective in improving MS symptoms in patients with moderate disability
Curing MS
Understanding what an MS cure means and what it takes
Prodromal MS

Progressive brain tissue loss precedes the onset of clinical MS by years
Sickness absence rate increases years before clinical onset of MS
Treatment Trials and MS Strategies

Early intensive treatment enhances long-term clinical outcomes
Anti-CD40L antibody safe and effective in a phase 2 study
Oral glycolipid shows promise in the treatment of MS, especially SPMS
Fenebrutinib shows rapid reduction of new Gd+ T1 lesions
Challenges of de-escalation versus discontinuation of highly effective DMTs in older MS patients
Biomarkers & Imaging
Retinal OCT markers hold promise for early MS diagnosis
χ-separation can assess the effects of tissue destruction in early MS lesions
